<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844192</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0452</org_study_id>
    <nct_id>NCT02844192</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Vancomycin in ICU Patients</brief_title>
  <acronym>PK-VANCO-ICU</acronym>
  <official_title>Pharmacokinetics of Vancomycin in ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is frequently under-dosed in ICU patients during the first 24-48 hours of
      treatment. Glomerular hyperfiltration syndrome, increased drug volume of distribution,
      vasopressor use, male sex and hypoalbuminemia are identified risk factor for vancomycin
      underdosing in ICU patients, among others.

      To date, bedside estimation of vancomycin volume of distribution is challenging, and new
      methods for optimizing drug administration are required.

      The Picco device is a moderately invasive hemodynamic monitoring system, providing parameters
      that may help estimation of vancomycin pharmacokinetics parameter.

      The aim of this study is to test whether addition of hemodynamic parameters would improve
      pharmacokinetics modelling of vancomycin concentration in ICU patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Akaike information criterion as a measurement of goodness of fit of pharmacokinetic modeling of vancomycin serum concentration</measure>
    <time_frame>week 1</time_frame>
    <description>All available vancomycin measurements during the first week of treatment will be included in the pharmacokinetics model.
All vancomycin dosages up to seven days of treatment will be used in a population pharmacokinetic model and an individual pharmacokinetic model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with under-dosage of vancomycin at day 2 of treatment</measure>
    <time_frame>day 2</time_frame>
    <description>under-dosage of vancomycin is defined by a vancomycin serum concentration below 15 mg/l on day 2 of treatment.</description>
  </secondary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Suspected Infection With Vancomycin Susceptible Bacterial Strains</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient hospitalized in intensive care unit

          -  under intravenous vancomycin started during current ICU hospitalization

          -  with at least one vancomycin serum concentration available

          -  under hemodynamic monitoring with the Picco ® device

        Exclusion Criteria:

          -  vancomycin treatment for less than 24 hours

          -  vancomycin concentration in serum unavailable

          -  rare comorbidities influencing vancomycin pharmacokinetics

               -  myeloma

               -  cystic fibrosis

               -  burn injury on more than 20 % of the body surface

          -  previous inclusion in present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe RICHARD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital de la Croix-Rousse - Réanimation, Surveillance Continue Médicales et Assistance Respiratoire,103 Grande Rue de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 21, 2016</last_update_submitted>
  <last_update_submitted_qc>July 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vancomycin</keyword>
  <keyword>under dosage</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

